Related Experiment Video
Updated: Jul 4, 2026

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Gene expression and methylation status of 14-3-3sigma in human renal carcinoma tissues
Shufang Liang1, Yuhuan Xu, Guobo Shen
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Abstract:
Loss of 14-3-3sigma expression mainly by methylation-mediated silencing has been reported in several human cancers, but the methylation status of 14-3-3sigma in human renal carcinoma is rarely studied so far. In this report, 14-3-3sigma expression was first examined by RT-PCR and immunohistochemistry, and further we investigated the methylation status by methylation-specific PCR and the correlation between 14-3-3sigma expression and its methylation. We found 14-3-3sigma expression was lost in 27 of 31 renal tissues including 16 renal carcinoma tissues, eight para-cancerous kidney tissues and seven normal kidney tissues. Among 16 renal carcinoma tissues, 14 cases had complete hypermethylation of 14-3-3sigma. Eight para-cancerous kidney tissues were almost completely methylated except one case had both methylation and unmethylation. Among seven normal kidney tissues, five cases had partial methylation, and the other two cases were completely methylated. In addition, 14-3-3sigma mRNA had weak expression in OS-RC-2 cells, but it increased with gradual demethylation after treatment by a demethylation agent, 5-aza-2'-deoxycytidine. In general, 14-3-3sigma mRNA was mostly unexpressed, and its DNA frequently hypermethylated within 14-3-3sigma coding region was closely associated with the gene silencing in cancerous and para-cancerous kidney tissues. 14-3-3sigma was also frequently methylated and almost silencing in normal kidney tissues. However, the methylation frequency was gradually reinforced with the extent of malignancy from normal to para-cancerous and cancerous kidney tissues.
Insights
14-3-3sigma gene expression is frequently lost in kidney tissues due to DNA hypermethylation. This epigenetic silencing increases with cancer progression, impacting normal, para-cancerous, and renal carcinoma tissues.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- 14-3-3sigma (also known as stratifin) is a tumor suppressor gene.
- Loss of 14-3-3sigma expression via methylation is implicated in various cancers.
- Its methylation status in human renal carcinoma remains understudied.
Purpose of the Study:
- To investigate the expression and methylation status of 14-3-3sigma in human renal tissues.
- To determine the correlation between 14-3-3sigma gene silencing and its DNA methylation.
- To assess methylation patterns across normal, para-cancerous, and cancerous kidney tissues.
Main Methods:
- Reverse Transcription Polymerase Chain Reaction (RT-PCR) for gene expression analysis.
- Immunohistochemistry for protein expression assessment.
- Methylation-Specific PCR (MSP) to evaluate DNA methylation status.
- In vitro demethylation using 5-aza-2'-deoxycytidine in OS-RC-2 cells.
Main Results:
- 14-3-3sigma expression was lost in 27 out of 31 renal tissues examined.
- Hypermethylation of 14-3-3sigma was observed in 14/16 renal carcinoma tissues.
- Methylation was also prevalent in para-cancerous and normal kidney tissues, increasing with malignancy.
- Demethylation treatment in OS-RC-2 cells partially restored 14-3-3sigma mRNA expression.
Conclusions:
- 14-3-3sigma gene silencing is strongly associated with DNA hypermethylation in renal tissues.
- The frequency and extent of 14-3-3sigma methylation increase with the progression of kidney malignancy.
- Epigenetic silencing of 14-3-3sigma is a common event in renal carcinogenesis and even in normal kidney tissue.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...

